TACE Combined With Sintilimab and Bevacizumab for Unresectable HCC
Condition: Hepatocellular Carcinoma Non-resectable Intervention: Drug: TACE combined with sintilimab and bevacizumab Sponsor: Second Affiliated Hospital of Guangzhou Medical University Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials